Trending Now
Cue Biopharma Inc (NASDAQ:CUE) Advances CUE-101 Dose Escalation Phase 1 Monotherapy...
Cue Biopharma Inc (NASDAQ:CUE) received encouraging results in the cohort 5 and cohort 4 dosing and got clearance from the SRC (Safety Review Committee)....
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Oncolytics Biotech® Inc. (NASDAQ:ONCY) Reports Positive ReoGlio Phase 1B Study Results...
Oncolytics Biotech® Inc. (NASDAQ:ONCY) has announced positive data from the investigator-sponsored, ReoGlio phase 1b study. The company is evaluating pelareorep combination with...
MAKE IT MODERN
LATEST REVIEWS
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) Announces CRV431 Study Results In Liver Disease
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) has announced results from its translational research study of CRV431, it's lead drug candidate. CRV431 demonstrated a decrease...
MAKE IT MODERN
PERFORMANCE TRAINING
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) Announce Positive PHALCON-EE Study Results Of Vonoprazan in Erosive...
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) announced that vonoprazan met the primary endpoints and core secondary superiority endpoints in PHALCON-EE, a vital third phase study...
iTeos Therapeutics (NASDAQ: ITOS) Sees Surge in Stock and Advances in Oncology Treatments and...
iTeos Therapeutics, Inc. (NASDAQ: ITOS), a trailblazer in the field of immuno-oncology, is witnessing significant strides both in the market and within...
Allena Pharmaceuticals Inc. (NASDAQ:ALNA) Commence Dosing In Phase 1 ALLN-346 Clinical Trial
Allena Pharmaceuticals Inc. (NASDAQ:ALNA) has announced the dosing of the first subject in Phase 1 clinical study of ALLN-346, an orally administered investigational urate-degrading...
Applied Molecular Transport Inc. (NASDAQ: AMTI) Announces Positive Results For AMT-101 Study
Applied Molecular Transport Inc. (NASDAQ: AMTI) announced positive results for its AMT-101 therapy. This treatment is for chronic pouchitis patients. The drug is GI-selective...
uniQure N.V. (NASDAQ: QURE) Doses First Two Subjects In the EU Clinical Study of...
uniQure N.V. (NASDAQ: QURE) has announced the dosing of the first two subjects in the European phase Ib/II clinical; study of AMT-130 in Europe....
MAKE IT MODERN
